Sherman Oaks, CA (July 24, 2003) -- The Spondylitis Association of America (SAA) today released the following statement regarding Enbrel™ (etanercept), the first biologic medicine approved to treat ankylosing spondylitis (AS) in the United States.

"On behalf of the more than 350,000 people in the United States who live with AS or a related disease, we applaud the FDA for the milestone of approving Enbrel to treat AS," said Jane Bruckel, BSN, RN, and Executive Director of the SAA. "The SAA believes that treatments, like Enbrel, can greatly enhance the quality of life for people with AS and that we should have as many options as possible to treat this disease, which can have a devastating effect on people's lives."

The mission of the SAA is to be a leader in the quest to cure AS and related disease and to empower those affected to live life to the fullest.

"SAA is working every day to advance our understanding of AS and to work towards a cure. We are encouraged that new breakthroughs in genetics will lead to a cure. However, until there is a cure, it is vital that people have appropriate treatment options. We are pleased that there is research continuing to bring new treatments to people living with AS or a related disease."

About Ankylosing Spondylitis
Ankylosing Spondylitis, often called arthritis of the spine, is a painful and progressive form of spinal arthritis that usually affects people under the age of 35 years. AS typically begins in the late teens and early twenties and can result in fusing of the spinal vertebrae, hips and other joints. Often misdiagnosed as "just back pain," or undifferentiated arthritis, AS can affect vision and internal organs as well. The SAA estimates that at least 350,000 people in the US suffer from AS; thought-leaders believe the number is closer to one million.

About SAA
For over 20 years, SAA has helped improve the lives of people with AS and its related diseases. The organization is committed to helping patients live life to the fullest. SAA has grown from a small, yet dedicated group of patients and their families, to a national organization with members throughout the United States. Today, SAA is the leading source of information of AS in the country, providing materials, events and services to people with AS and related diseases. SAA is a driving force in national research efforts and works with medical thought-leaders in the United States on research and clinical studies to improve patient care.

For more information about AS, related diseases and the SAA, visit: www.spondylitis.org or call toll-free: 800.777.8189.

Media inquiries should call Robin Shapiro at 206.849.8839.